U.S. CDC will request a moratorium on  Johnson & Johnson COVID-19 vaccine

U.S. CDC will request a moratorium on  Johnson & Johnson COVID-19 vaccine.  According to the “New York Times” report on the 13th, after multiple cases of thrombosis, the United States will request the suspension of the use of Johnson & Johnson’s COVID-19 vaccine. It is reported that six people in the United States have developed a rare disease involving blood clots within about two weeks after receiving the Johnson & Johnson vaccine.

According to the report, the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) will stop the use of Johnson & Johnson vaccines at federal locations and urge states to do the same during safety investigations.

Before the US stock market on April 13 (Tuesday), Johnson & Johnson (JNJ.US) shares fell, and the stock fell 2.86% to $157.01. After the occurrence of thrombosis, the United States will require the suspension of the use of Johnson & Johnson’s COVID-19 vaccine. As of April 12, Johnson & Johnson vaccine has been injected with more than 6.8 million doses in the United States.

The U.S. Food and Drug Administration said that the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have reviewed 6 cases of a rare and serious blood clot after receiving a Johnson & Johnson vaccine in the United States. It is recommended to suspend the use of Johnson & Johnson’s COVID-19 vaccine until the case of thrombosis caused by the Johnson & Johnson vaccine is reviewed.

Other news:

On the 13th, local time on the 13th, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) issued a statement that the use of Johnson & Johnson’s COVID-19 vaccine is recommended to be suspended due to thrombotic symptoms. CNN reported that all federal health agencies in the United States will immediately suspend the use of the vaccine.

The report quoted a White House official as saying that this statement means that all federal health agencies, including large-scale COVID-19 vaccination sites, community health centers, and other federal health agencies, will immediately suspend vaccinations against Johnson & Johnson. Although the recommendation is also applicable to all states in the United States, given that each state has received a separate supply of vaccines, whether to suspend vaccination will be decided by each locality.

The reason why the Johnson & Johnson vaccine is recommended to be discontinued is that some vaccinators have experienced side effects that are not included in the emergency use license of the vaccine. At present, 6 people in the United States have reported “rare and serious thrombosis.” White House officials emphasized that this side effect is extremely rare, and it is hoped that medical institutions will have time to learn about various side effects and find the best treatment.

Related News on Mar 12: 

The World Health Organization announced today that the COVID-19 vaccine developed by Johnson & Johnson will be included in the emergency use list and approved for promotion in all countries. At the same time, although some countries have stopped using the AstraZeneca/Oxford vaccine (AstraZeneca/Oxford) because of concerns about the possibility of thrombosis, the WHO stated that it has not found a causal link between the two.

After the European Medicines Agency approved the Johnson & Johnson vaccine yesterday, the WHO announced today that it was included in the emergency use list through an expedited procedure.

Prior to this, the WHO has approved the emergency use of two COVID-19 vaccines. The Pfizer/Biotech vaccine was approved on December 31, 2020, and two versions of the AstraZeneca/Oxford vaccine were approved on February 15, 2021.

The first single-dose vaccine approved

The Johnson & Johnson vaccine is the first single-dose vaccine approved by the WHO, which will help roll out in all countries.

The large amount of clinical trial data shared by Johnson & Johnson also shows that the vaccine is also effective for the elderly.

Although this vaccine needs to be stored at minus 20°C, which may cause challenges in some environments, at 2-8°C, this vaccine can still be stored for three months and has a longer period of two years. Shelf life.

The WHO will convene a meeting of its immunization expert strategic advisory group next week to formulate recommendations on the use of Johnson & Johnson vaccine.

(source:internet, reference only)

Disclaimer of medicaltrend.org